International Journal of Radiation Oncology*Biology*Physics
Original contributionRadiotherapy alone in carcinoma of the intact uterine cervix according to G. H. Fletcher guidelines: A french cooperative study of 1383 cases
References (23)
- et al.
Results of radiotherapy alone in 581 patients with stage II carcinoma of the uterine cervix
Int. J. Radiat. Oncol. Biol. Phys.
(1985) - et al.
Dose-volume analysis and the prevention of radiation sequelae in cervical cancer
Radiother. Oncol.
(1987) - et al.
A quantified approach to the analysis and prevention of urinary complication in radiotherapeutic treatment of the cancer of the cervix
Int. J. Radiat. Oncol. Biol. Phys.
(1987) - et al.
Cancer of the uterine cervix. Dosimetric guidelines for prevention of late rectal and rectosigmoid complications as a result of radiotherapeutic treatment
Int. J. Radiat. Oncol. Biol. Phys.
(1982) - et al.
Transperitoneal pelvic lymphadenectomy following supervoltage irradiation for squamous cell carcinoma of cervix
Am. J. Obstet. Gynecol.
(1958) - et al.
Treatment of carcinoma of the uterine cervix by remotely controlled after-loading intracavitary radiotherapy with high dose rate: A comparative study with a low dose rate system
Int. J. Radiat. Oncol. Biol. Phys.
(1983) Quelques réflexions a propos d'une statistique générale portant sur 3327 cas d'épithélioma du col de l'utérus traités par les radiations de 1919 à 1947 à la Fondation Curie
Gynéc. Obst.
(1954)- et al.
Propositions pour une définition commune des points de référence en curiethérapie gynécologique
J. Radiol. Electrol.
(1977) Annual report on the results of treatment in gynecological cancer. Statements of results obtained in 1976 to 1978
Radiumhemmet
(1985)
Overall results in radiotherapy for carcinoma of the cervix: Modern treatment
Clin. Obst. Gynec.
Cited by (157)
Low-Dose-Rate versus High-Dose-Rate intracavitary brachytherapy in cervical cancer - Final Results of a Phase III randomized trial
2021, BrachytherapyCitation Excerpt :Brachytherapy is quintessential and a good quality intracavitary brachytherapy has shown to improve both local control and disease free survival. (3,4) Low-dose-rate (LDR) intracavitary brachytherapy has been the time-tested brachytherapy dose rate system for cervical cancer (5). Since the introduction of high-dose-rate (HDR) in late 1980′s, there has been a steady shift in brachytherapy dose rate system with > 85% utilization rates reported. (6)
Evaluation of outcomes in patients of cervical Cancer with lower one third vaginal involvement: A single institutional experience
2020, Gynecologic OncologyCitation Excerpt :In our study, we have compared survival of IIIA and IIIB patients with lower vaginal involvement for this cohort. Five-year OS of stage IIIA patients in previous studies was higher than that of stage IIIB with 58%–62% and 34%–50% [9,10] [7,8] respectively which is matching with our results [3 year DFS (71% vs 56%; p = .02) and 3 years OS (76% vs 66%; p = .01) on univariate analysis]. On multivariate analysis, we did not find any significant difference in survival between two groups with trend of better survival in stage IIIA group as compared to stage IIIB.
Cervical Cancer
2015, Clinical Radiation OncologyUtility of preoperative ferumoxtran-10 MRI to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN 6671/GOG 0233
2015, European Journal of Radiology Open